Trifluridine–Tipiracil with and without Bevacizumab in Colorectal Cancer

20261 citationsJournal Article

Authors

Maliha Nusrat · Memorial Sloan Kettering Cancer Center

Ruizhi Zhao · Taiho Oncology (United States)

Nadeem Khan · Taiho Oncology (United States)

Y. Wang · Concert Pharmaceuticals (United States)

Kathryn Penney · Concert Pharmaceuticals (United States)

Christopher Cann · Fox Chase Cancer Center

Tehseen Salimi

Abstract

This U.S.-based real-world observational study found that FTD-TPI+bev was associated with longer rwOS compared with FTD-TPI in patients with mCRC. These findings align with the results of the SUNLIGHT clinical trial. (Funded by Taiho Oncology, Inc. and others.).

Topics & Keywords

Colorectal Cancer Treatments and Studies Cancer Research and Treatments Oral health in cancer treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: NEJM Evidence

Volume 5, Issue 3, pp. EVIDoa2500120-EVIDoa2500120

DOI: 10.1056/evidoa2500120

Field-Weighted Citation Impact: 46.84